Taking on heart disease
At Johnson & Johnson, we have an unrelenting vision to ease the tremendous global burden of cardiovascular disease. From anticoagulation, to advanced mapping and catheter ablation to treat atrial fibrillation, to cutting-edge technology that enables heart recovery through temporarily assisting the pumping function of the heart, to next generation investigational antithrombotics with the potential to help address unmet needs in acute coronary syndrome and stroke, our medical technologies and therapeutics are helping treat some of the most prevalent heart conditions, driving better outcomes and lasting impact for patients.
Innovating in Health&Care
5 things we now know about atrial fibrillation
More than 37.5 million people worldwide are affected by this common type of heart arrhythmia—and by 2050, the number of cases will increase by 60%. Learn the facts behind this heart condition, plus one patient’s diagnosis story.
Do you know what heart failure is? (Hint: It’s probably not what you think)
Learn about the advances Johnson & Johnson is making to help turn heart failure into heart recovery for the millions of adults in the U.S. living with the condition, which occurs when the heart muscle isn’t able to pump blood as well as it should.
Key things we now know about peripheral artery disease
The common circulatory condition is a leading cause of amputations in the U.S. Learn why Black Americans are disproportionately affected and how Johnson & Johnson is helping to raise awareness about the disease.
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
Inside the science of strokes
Strokes are responsible for around 140,000 deaths a year in the United States alone. Learn how Johnson & Johnson is innovating to help change that stat.
What is cardiac ablation?
Learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
More from Johnson & Johnson
This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others
Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.
After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists
Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.
How Johnson & Johnson is working to get medications to people around the world who need them most
In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.